Discontinued Product

O-2050 (Cat. No. 1655) has been withdrawn from sale for commercial reasons.
Description: Putative CB1 antagonist; displays mixed activity at CB receptors
Chemical Name: (6aR,10aR)-1-Hydroxy-3-(1-Methanesulfonylamino-4-hexyn-6-yl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d]pyran
Purity: ≥97% (HPLC)
Citations (8)
Literature (2)

Biological Activity for O-2050

O-2050 is an originally defined as a high affinity cannabinoid CB1 receptor silent antagonist. Acts as a partial agonist in inhibiting forksolin-induced cyclic AMP stimulation (EC50 = 40.4 nM). Decreases food intake and stimulates locomotor activity in rodents. Antagonizes effects of CP55,940 (Cat. No. 0949) in vitro.

Licensing Information

Sold under license from VCU-IPF

Technical Data for O-2050

M. Wt 417.56
Formula C23H31NO4S
Storage Store at -80°C
Purity ≥97% (HPLC)
CAS Number 1883545-42-3
PubChem ID 16102146
Smiles OC1=CC(CC#CCCCNS(=O)(C)=O)=CC3=[C@@]1[C@@H]2CC(C)=CC[C@H]2[C@@](C)(C)O3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for O-2050

Certificate of Analysis / Product Datasheet
Select another batch:

References for O-2050

References are publications that support the biological activity of the product.

Gardner and Mallet (2006) Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist.' Eur.J.Pharmacol. 530 103 PMID: 16380113

Martin et al (2002) Agonists and silent antagonists in a series of cannabinoid sulfonamides. Symposium on the Cannabinoids, International Canna

Wiley et al (2011) Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB1 receptor antagonist. Eur.J.Pharmacol. 651 96 PMID: 21114999

View Related Products by Target

Keywords: O-2050, O-2050 supplier, CB1, silent, antagonists, cannabinoids, receptors, cb1r, receptor, Receptors, 1655, Tocris Bioscience

8 Citations for O-2050

Citations are publications that use Tocris products. Selected citations for O-2050 include:

Pinheiro et al (2016) Hierarchical glucocorticoid-endocannabinoid interplay regulates the activation of the nucleus accumbens by insulin. Brain Res Bull 124 222 PMID: 27208730

Keimpema et al (2013) Diacylglycerol lipase α manipulation reveals developmental roles for intercellular endocannabinoid signaling. Nat Commun 3 2093 PMID: 23806960

Brents et al (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6 e21917 PMID: 21755008

Alpár et al (2014) Endocannabinoids modulate cortical development by configuring Slit2/Robo1 signalling. BMC Ophthalmol 5 4421 PMID: 25030704

Reviews for O-2050

There are currently no reviews for this product. Be the first to review O-2050 and earn rewards!

Have you used O-2050?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Cannabinoid Receptor Ligands Scientific Review

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.